Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK4 | Q16654 | 1/20 | 0.53 |
| ▸ | GRM1 | Q13255 | 8/20 | 0.49 |
| ▸ | GRM5 | P41594 | 7/20 | 0.49 |
| ▸ | CNR1 | P21554 | 2/20 | 0.48 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | WDR5 | P61964 | 2/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | TNF | P01375 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | CDK9 | P50750 | 3/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19701846 | 0.91 | PDK4 (0.51) | PDK4GRM1GRM5CNR1HTR6 | |
| SCHEMBL21424861 | 0.89 | PDK4 (0.49) | PDK4GRM1GRM5CNR1HTR6 | |
| SCHEMBL31342561 | 0.88 | PDK4 (0.50) | PDK4GRM1GRM5CNR1HTR6 | |
| SCHEMBL31342347 | 0.87 | PDK4 (0.49) | PDK4GRM1GRM5CNR1HTR6 | |
| SCHEMBL21404031 | 0.87 | PDK4 (0.49) | PDK4GRM1GRM5CNR1HTR6 | |
| SCHEMBL22957461 | 0.86 | PDK4 (0.53) | PDK4GRM1GRM5CNR1HTR6 | |
| SCHEMBL29707360 | 0.86 | PDK4 (0.53) | PDK4GRM1GRM5CNR1HTR6 | |
| SCHEMBL29197065 | 0.86 | PDK4 (0.53) | PDK4GRM1GRM5CNR1HTR6 | |
| SCHEMBL15556190 | 0.85 | CNR1 (0.55) | PDK4GRM1GRM5CNR1HTR6 | |
| SCHEMBL31342210 | 0.85 | CNR1 (0.55) | PDK4GRM1GRM5CNR1HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| WO-2025049820-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | STAT6, NCOR2, NCOR1 | PDK4 2483/4885GRM1 782/4885GRM5 1981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.